An observational study in Prostate Cancer, Adenocarcinoma of the Prostate and Locally Advanced Prostate Carcinoma, sponsored by Universitaire Ziekenhuizen KU Leuven. Recruiting at 4 sites in Belgium. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-22.
Sponsored by Universitaire Ziekenhuizen KU Leuven · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Prostatic Neoplasms by Universitaire Ziekenhuizen KU Leuven — 8 open to participants now, 11 under way, 3 of them phase 3. Prostatic Neoplasms · Universitaire Ziekenhuizen KU Leuven.
Among the 12 studies in Prostatic Neoplasms by Universitaire Ziekenhuizen KU Leuven, this one is one of 3 that started in 2020, is one of 2 observational ones, reaches primary completion later than 10 of the 10 other live ones, and was the 9th registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →8 of the 12 studies in Prostatic Neoplasms by Universitaire Ziekenhuizen KU Leuven are open now, in 1 country. Recruiting first, the newest first:
Universitaire Ziekenhuizen KU Leuven · Sites in Belgium
Ages 18+ · Men only
Universitaire Ziekenhuizen KU Leuven · Sites in Belgium
Men only
Universitaire Ziekenhuizen KU Leuven · Sites in Belgium
Ages 18+ · Men only
Universitaire Ziekenhuizen KU Leuven · Sites in Belgium
Men only
Universitaire Ziekenhuizen KU Leuven · Sites in Belgium
Ages 50–75 · Men only
By country, each count listing its studies:
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 3
First in 2017; this study’s year is marked. 3 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 5,000 is above the median of 200 across 1,312 observational studies indexed under Prostatic Neoplasms.
Median enrollment 131 across the 10 interventional studies, 2,623 across the 2 observational. None of them has completed or been terminated yet.
This tab as a report to print or save as PDF → With an account.
Universitaire Ziekenhuizen KU Leuven is the lead sponsor of 965 studies on the registry; 268 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
2 of the studies in Prostatic Neoplasms by Universitaire Ziekenhuizen KU Leuven that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05352178Phase 3Universitaire Ziekenhuizen KU LeuvenMetastasis-directed Therapy for Oligorecurrent Prostate Cancer | 2027-04-25 |
| NCT05344235Universitaire Ziekenhuizen KU LeuvenObservational Study on Extreme Hypofractionation for Localized Prostate Cancer | 2027-04 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies in Prostatic Neoplasms by Universitaire Ziekenhuizen KU Leuven, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the use of a digital solution, integrated into the electronic health record, for prospective and structured reporting of clinical and patient-reported outcomes for patients diagnosed with localized or locally advanced prostate cancer.
All patients with newly diagnosed histologically proven localized and locally advanced prostate cancer referred to one of the participating sites will be eligible to be enrolled in the cohort.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Localized prostate cancer (cT1a-T2c N0 M0) refers to the clinical condition where cancer is confined to the prostate gland, in the absence of lymph node invasion or metastases. Locally advanced refers to the extension of the tumor beyond the capsule of the prostate (cT3-T4) or the clinical presence of nodal invasion (cN+), without metastases.
Other: standard of care
No other procedures than those performed during the usual care for prostate cancer patients will be done. No study medication will be provided as part of participation. Clinical outcomes will be reported via predefined electronic forms, integrated into the electronic health record (EHR). Patient-reported outcomes will be collected electronically. All treatment decisions will be made at the discretion of the investigator or treating physician.
Assessment of systematically reporting a standardized set of predefined clinical parameters
The proportion of patients who are enrolled in the registry over the total localized and locally advanced prostate cancer patients
Time frame: up to 10 years after diagnosis
Assessment of systematically collecting a predefined set of patient-reported outcomes
The proportion of patients who completed all questionnaires over the total of questionnaires send.
Time frame: up to 10 years after diagnosis
Occurence of disease recurrence/progression
Biochemical prostate specific antigen (PSA) recurrence/progression and recurrence/progression based on medical imaging
Time frame: up to 10 years after diagnosis
General quality of life
Assessment of health-related quality of life in prostate cancer patients. Measured by EORTC Quality of Life Questionnaire C30 (QLQ-C30). The EORTC QLQ-C30 is a generic QoL questionnaire designed to cover issues important to all cancer patients
Time frame: at diagnosis, 6 months, 1 year, and annually up to 10 years after diagnosis
Prostate cancer specific quality of life
Measured by Extended Prostate cancer Index Composite 26 (EPIC26). EPIC-26 is a validated instrument that measures the quality of life across 5 disease-specific domains: urinary incontinence, urinary obstruction and irritation, bowel-related symptoms, sexual dysfunction, and hormonal symptoms.
Time frame: at diagnosis, 6 months, 1 year, and annually up to 10 years after diagnosis
Overall Survival (OS)
Overall survival is defined as the time from enrollment to date of death due to any cause.
Time frame: up to 10 years after diagnosis
Prostate Cancer (PC)-related Mortality (PM)
PC-related mortality is the death due to prostate cancer.
Time frame: up to 10 years after diagnosis
Plan to share: Undecided
No publications or documents are linked to this record.
Started Oct 2020 (actual). Primary completion is estimated for Oct 2030, 120 months after the start.
Of 542 non-industry observational studies under Prostatic Neoplasms, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 162. This study's planned 120 months is above that.
Counting every sponsor, half of 651 studies reached it within 60 months; a quarter within 28 and three quarters within 141.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universitaire Ziekenhuizen KU Leuven →